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Dietary nitrate has beneficial effects on health maintenance and prevention of lifestyle-related diseases 
in adulthood by serving as an alternative source of nitric oxide (NO) through the enterosalivary nitrate–
nitrite–NO pathway, particularly when endogenous NO generation is lacking due to vascular 
endothelial dysfunction. However, this pathway is not developed in the early postnatal period due to a 
lack of oral commensal nitrate-reducing bacteria and less saliva production than in adults. To 
compensate for the decrease in nitrite during this period, colostrum contains the highest amount of 
nitrite compared with transitional, mature, and even artificial milk, suggesting that colostrum plays an 
important role in tentatively replenishing nitrite, in addition to involving a nutritional aspect, until the 
enterosalivary nitrate–nitrite–NO pathway is established. Increasing evidence demonstrates that breast 
milk rich in nitrite can be effective in the prevention of neonatal infections and gastrointestinal diseases 
such as infantile hypertrophic pyloric stenosis and necrotizing enterocolitis, suggesting that 





























Recent evidence suggests that dietary nitrate and nitrite serve as an alternative source of nitric oxide 
(NO); it has initiated a paradigm shift from considering nitrate and nitrite as inert endproducts of NO 
to the realization that they are key regulators for several physiological roles in preventing lifestyle-
related diseases in adulthood (1).  
However, little is known about the preventive effects of dietary nitrate and nitrite on diseases in the 
neonatal period. For neonates, milk is the only nutrition source. Breast milk, particularly colostrum, 
contains the highest amount of nitrite compared with transitional, mature, and even artificial milk (2). 
While the immunological and nutritional benefits of breastfeeding have been well documented (3), the 
physiological significance of nitrate and nitrite in breast milk for neonates remains unclear. When 
considering the conversion of dietary nitrate and nitrite to NO bioactivity in relation to neonatal 
physiology, a high nitrite concentration in breast milk may have some physiological implications for 
neonates. This review aims to discuss the physiological roles of dietary nitrite in the early neonatal 
period, particularly focusing on the bioactivation of nitrite in breast milk and its preventive effects on 
infectious and gastrointestinal diseases frequently encountered in early infancy.  
 
NITRATE AND NITRITE IN BREAST MILK AND THEIR SAFETY 
Excess dietary nitrate and nitrite in infants are related to methemoglobinemia (blue-baby syndrome), 
in which the nitrite-mediated oxidation of ferrous iron (Fe2+) in hemoglobin (Hb) to the ferric state 
(Fe3+) causes hypoxia and cyanosis, resulting in blue skin color (4,5). Infants younger than 6 months 
old are susceptible to nitrate-induced methemoglobinemia due to easy oxidation of fetal Hb by reaction 
with nitrite (6) and an immature methemoglobin (metHb) reductase system (7, 8). In addition to these 
physiological conditions in neonates, in the reported cases of blue-baby syndrome, the infants were 
fed formula milk prepared with well water contaminated with excess nitrate (derived from fertilizers, 
approximately 10–66 mg/L of nitrate in water) that can be reduced to large amounts of nitrite (5). A 
considerable amount of nitrite may have been loaded in these infants, leading to methemoglobinemia. 
Based on the lessons and subsequent analyses of the infant cases of methemoglobinemia, the World 
Health Organization (WHO) announced that the acceptable daily intake (ADI) for nitrate and nitrite 
for humans was 3.7 and 0.06 mg/kg body weight (BW)/day, respectively, which were derived from the 
data calculated from the doses of <500 mg/kg BW/day of sodium nitrate that were harmless to rats and 
dogs (9).   
Regarding infants solely dependent on milk feeding for their nutrition, they ingest some nitrate and 
nitrite from breast milk (0.19 and 0.08 mg/100 mL, respectively) and formula milk (0.02–3.48 and 
0.00005–0.03 mg/100 mL, respectively) (8). However, these intakes are within the ranges that do not 
cause clinical problems because the doses are far lower than the reported amounts of nitrate and nitrite 
from the well water contaminated with fertilizers. As long as the water for milk preparation is not 
bacterially contaminated, the absorbed nitrate that has not been converted to nitrite can be readily 
excreted in the urine without adverse effects (10). Even if the mother ingests water with very high 
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nitrate concentrations (up to 100 mg/L), they are not reflected in breast milk (11), suggesting that 
breastfeeding infants are generally not at risk of methemoglobinemia (12).  
 
PHYSIOLOGICAL ROLES OF DIETARY NITRATE AND NITRITE IN THE GENERATION 
OF NO BIOACTIVITY  
Dietary nitrate abundant in green leafy vegetables is absorbed from the upper gastrointestinal tract into 
systemic circulation, and approximately 60% is excreted via the kidney within 48 h (13). However, 
25% of nitrate is actively taken up from circulation by the salivary gland and secreted into saliva. This 
salivary nitrate is reduced to nitrite by commensal bacteria residing on the surface of the tongue (14). 
Then, the salivary nitrite is swallowed to the acidic stomach, protonated to form nitrous acid, followed 
by gastric NO generation or reentering into circulation as nitrite from the upper gastrointestinal tract 
to form the nitrite pool in the blood and tissues (referred to as enterosalivary nitrate–nitrite–NO 
pathway) (15). NO bioactivities, such as blood pressure reduction, correspond with the point of peak 
plasma nitrite concentration, suggesting that basal nitrite levels in the blood are significant contributors 
to NO bioactivity (16).   
There are two sources of nitrite in whole blood and tissues (Fig. 1). The endothelial NO synthase 
(eNOS)-derived NO accounts for a significant portion of endogenously produced nitrite because 
plasma nitrite levels decrease by 70% by eNOS knockout in fasting mice (17, 18). However, dietary 
nitrate and nitrite also contribute to 30%–50% of the circulating pool of these anions, as evidenced in 
the experiment using nitrate- and nitrite-deficient diets (19). The nitrite in the pool is transduced to NO 
bioactivity by circulating and tissue-bound nitrite reductases (1). Several mechanisms to reduce nitrite 
to NO have been reported, including enzymatic reduction by xanthine oxidase, NO synthase, 
components of the mitochondrial electron transport chain, and nonenzymatic acidic disproportionation 
(20). However, these mechanisms require low pH and oxygen saturation, particularly in pathological 
conditions; therefore, they do not readily work under physiological hypoxia. However, the role of 
erythrocytes as a physiological transporter of NO bioactivity has garnered attention recently. Nitrite-
mediated inhibition of platelet activation requires the presence of erythrocytes; nitrite has no effect in 
the absence of erythrocytes. This action is abrogated by a NO scavenger (21). Tsuchiya et al. showed 
that the dietary isotope of nitrite (15NO2
- in drinking water) is taken up by erythrocytes and forms Fe-
15NO Hb in circulation with subsequent improvement of renal injuries caused by nitro-L-arginine 
methyl ester hydrochloride (L-NAME, an NOS inhibitor)-induced hypertension in rats (22). These 
results suggest that erythrocyte-associated nitrite bioactivation may be mediated through NO and 
subsequent NO-Hb formation. 
Nitrite in erythrocytes is reduced to NO by Hb, which is deoxygenated during artery-to-vein transit, 
resulting in NO release to other thiol acceptors (cysteine and glutathione) to form plasma and other 
cellular protein S-nitrosothiols (SNOs), which are vasoactive at concentrations as low as 1–5 nM (23, 
24), and convey the NO signal to the vessel walls as well as other peripheral tissues and organs. 
However, considering the rapid and strong scavenging of NO by Hb in erythrocytes, the question arises 
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as to how NO bioactivity escapes the erythrocytes. Once NO is formed in the erythrocytes, it must 
escape rapid scavenging by the intra-erythrocytic Hb. Many hypotheses have been proposed, such as 
nitrite reduction being limited to erythrocyte membrane compartments and production of another 
stable species, including nitrosothiol or N2O3 (a potent S-nitrosating agent) formation. Stamler et al. 
have reported that the erythrocyte-dependent vasodilation mechanism is related to the nitrosation of 
conserved Cys93 residue in the Hb β-chain (S-nitrosated Hb [SNO-Hb] formation) by NO transfer 
from Fe-NO Hb (24). Roche et al. reported that S-nitrosothiol formation such as S-nitrosoglutathione 
could occur through a metHb-nitrite-mediated N2O3 formation, and serve as a source of erythrocyte-
derived and exportable bioactive NO (25). Other reports also propose a mechanism in which an 
increased affinity of metHb-NO or Hb-NO+ for the erythrocyte membrane could lead to NO escape 
through nitrosylation of anion exchange protein (AE1)(26), suggesting a role of nitrosation of 
erythrocyte membranes in the escape of NO bioactivity.  
Although there may be other biochemical pathways of nitrite bioactivation that remain to be 
discovered, the detailed in vivo research is now ongoing (27-31), and further discussion will not be 
covered in this review. 
 
POSTNATAL DECREASE IN PLASMA NITRITE LEVELS 
In contrast to adults in whom the enterosalivary nitrate–nitrite–NO pathway is already being 
established, some consideration may be needed to determine whether this pathway is available in 
neonates (32). In animal models, the plasma nitrite levels in fetal sheep fall immediately after umbilical 
cord ligation and initiation of pulmonary ventilation (more than 60% decrease in plasma nitrite levels 
within 15 min after birth) (Fig. 2) (33). In humans too, the plasma nitrite levels in neonates rapidly fall 
at birth (from 0.18 ± 0.02 to 0.08 ± 0.02 μmol/L) and remains lower than those in adults for the first 
few weeks of life (34). This may be associated with dramatic circulatory changes from the placental 
to pulmonary circulation at birth (33, 34). Several reasons may account for this physiological decrease 
in plasma nitrite levels. First, the placental tissue constitutes a significant source of nitrite toward the 
fetus that is lost immediately after umbilical cord ligation at birth (6,33). The second reason may be 
the reaction of NO with superoxide generated by oxygenation to form peroxynitrite following 
pulmonary respiration. The peroxynitrite generated at birth not only prevents newborns from bacterial 
infection, but also scavenges NO away from nitrite generation (35, 36), possibly reflecting a rapid 
decrease in the plasma nitrite levels in newborns after birth. 
In addition to the circulatory and respiratory changes at birth, other factors also lower the plasma 
nitrite levels in the neonatal periods due to the immature enterosalivary nitrate–nitrite–NO pathway 
(34). First, the nitrate levels in milk and formula are lower than in foods in adulthood, resulting in less 
nitrate ingestion in infants (0.12 mg/kg BW/day) than in adults (0.7.3.0 mg/kg BW/day). Second, the 
saliva production rates are lower in newborns than in adults. Third, nitrate reduction to nitrite in the 
oral cavity by commensal bacteria is approximately ten-fold less in neonates than in adults. Fourth, 
the newborn stomach produces much less NO from swallowed nitrite than that of adults due to high 
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gastric pH. Fifth, newborn urinary nitrite concentrations are significantly higher than those of the adult 
(33), possibly because of the lack of carbonic anhydrase-mediated reabsorption of nitrite in the 
newborn kidney (37). Therefore, these factors that occur after birth may physiologically reduce NO 
bioactivity during the first weeks of the neonatal period (Fig. 3).  
 
BREAST MILK MAY COMPENSATE FOR NITRITE DECREASE IN THE EARLY 
POSTNATAL PERIOD 
Because the endogenous reduction of nitrate to nitrite is absent in the early postnatal period (38), the 
enterosalivary nitrate–nitrite–NO pathway, which contributes to forming a stable nitrite pool in the 
blood (Fig. 1), has not yet been established immediately after birth (32). Therefore, breast milk rich in 
nitrite may be necessary to replenish nitrite to compensate for the decrease in nitrite in the early 
postnatal period.  
Breast milk is the most perfect food for infants, but the nutritional quality and characteristics of 
breast milk change over time. Colostrum contains immune-protective factors (e.g., secretory 
immunoglobulin IgA, lactoferrin, leukocytes, and epidermal growth factor), which are more 
concentrated in the colostrum of mothers who deliver preterm infants (39). Considering that colostrum 
contains lower lactose concentrations than mature breast milk, its primary function is likely to be 
immunological rather than nutritional (40). Colostrum contains higher nitrite and lower nitrate 
concentrations than transition and mature breast milk (Table 1). According to the human study by Hord 
(2), the mean nitrite concentrations are 0.08 ± 0.02 mg/100 mL in colostrum and 
0.001 ± 0.001 mg/100 mL in transition and mature breast milk (Tables 1), giving the average daily 
nitrite intake of 0.2 mg/ mg/kg BW/day in colostrum and 0.0027 mg/kg BW/day in transition and 
mature breast milk (as calculated according to 3.0 kg BW and 750 mL/day, commonly used reference 
volume of intake in infants based on the study of the US Food and Nutrition Board, Institute of 
Medicine, National Academy of Science) (41) (Tables 2).     
Iizuka et al. also measured the nitrite and nitrate concentrations in the breast milk collected from 
Japanese women on postpartum days 2–5, which showed 19.3–82.4 μM/L (mean ± SD, 
43.6 ± 5.3 μM/L) of nitrite, significantly higher than that in commercial formula milk (ranging from 
8.4 to 25.5 μM/L [mean ± SD, 14.2 ± 5.3 μM/L] of nitrite). Although the Joint Food and Agricultural 
Organization/WHO has set the ADI for the nitrate and nitrite ions at 3.7 and 0.06 mg/kg BW/day, 
respectively, when taking an average nitrite concentration of 43.6 μM/L (or 2.0 mg/L) in colostrum 
(42), the total daily nitrite exposure to nursing infants is roughly 0.5 mg/kg BW/day (assuming the 
daily intake of breast milk is approximately 250 mL/kg BW) or 8.3-fold higher than the ADI for nitrite 
(Table 2). Exceeding the ADI limits with the usual intake levels of breast milk indicates that these 
regulatory limits may not have a rational basis when applied to food sources of nitrate and nitrite for 
early infants. Higher nitrite concentrations in colostrum may be for temporary assistance until dietary 
nitrate in the milk can be effectively processed via the enterosalivary pathway, which may play an 
important role in adaptation to the gastrointestinal, respiratory, and circulatory systems in the perinatal 
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period (discussed later). Kanematsu et al. demonstrated that in rats fed with dietary nitrite, renal 
injuries caused by L-NAME-induced hypertension significantly improved (43). The dietary dose of 
nitrite used in this study (0.1 and 1.0 mg/100 mL of nitrite in drinking water) and amount of nitrite the 
rats drank (0.1 and 1.0 mg/kg BW/day, respectively, calculated as 300 g of BW and 30 mL of water 
intake/day) are almost equivalent to the dose in human colostrum and daily nitrite consumption of 
neonates in the study by Iizuka (0.2 mg/100 mL in colostrum and 0.5 mg/kg BW/day intake) (Table 
2).  
However, for convenience, daily intakes of nitrite/nitrate in breast milk (mg/kg/day) presented here 
are the calculated amounts. Therefore, the actual intake of breast milk varies among individuals and 
possibly with a tendency of smaller intake in the early postnatal period than thereafter. In Iizuka’s 
study (42), NO production in the stomach during each intake of breast milk was obviously higher than 
that of formula milk (Fig. 4), suggesting that the physiological amounts of nitrite in human colostrum 
are a source of NO and may be relevant to the subsequent generation of NO metabolites in the stomach, 
as well as NO bioavailability in the systemic circulation (43).  
In this short review, taking into account the fact that the nitrite in colostrum increases temporarily, 
we will discuss how colostrum of breast milk, rich in nitrite is physiologically involved in the 
transitions from the fetus to the newborn at birth. 
 
CLINICAL IMPLICATIONS OF NITRITE IN BREAST MILK FOR INFANT NURSING  
Until the oral flora settles in early infancy, high nitrite levels in breast milk may play important roles 
in the physiological adaptation to extrauterine life. Recent research has provided scientific evidence 
for promoting breastfeeding to prevent diseases frequently encountered in early infancy.  
 
Prevention of Postnatal Infections 
The sources of nitrate and nitrite in breast milk are not well known. The amount of nitrate ingested by 
the mother does not affect the nitrate concentration in the breast milk, suggesting that active regulation 
of nitrate transport exists in the mammary tissues. However, xanthine oxidase (XO) in breast milk is 
important for NO generation (44). XO is a cellular redox enzyme homologous to bacterial nitrate 
reductase and is highly expressed in mammary epithelial cells. During lactation, these cells synthesize 
milk fat globules that are packaged by a membrane consisting of phospholipids and XO. XO, which is 
highly expressed in the globules in the first few weeks postpartum, can produce superoxide and 
hydrogen peroxide in the catalytic process of hypoxanthine to uric acid using oxygen as an electron 
acceptor (45). XO can produce NO using nitrate and nitrite as electron acceptors, leading to the 
subsequent generation of peroxynitrite, a potent bactericidal oxidant, following the combination of NO 
and superoxide (46). Stevens et al. showed XO-mediated antibacterial properties in breast milk against 
Escherichia coli and Salmonella enteritidis in an in vitro culture study (47). These reactive oxygen 
species (ROS) and reactive nitrogen species are generated during lactation with antimicrobial 
properties in the breast milk and gastrointestinal tracts, which may be required in the neonatal period 
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when neonates are vulnerable to various infections. This period coincides with the high nitrite levels 
in breast milk and provides potent protection from microbial infections, particularly in the period when 
the neonatal stomach is less acidic, ranging between pH4 and pH6 for the first few days after birth 
(48). 
Iizuka et al. analyzed the intragastric generation of NO gas in neonates fed with breast or formula 
milk. They collected stomach gas 1 h after feeding once daily for 1–5 days postpartum to measure NO 
using a chemiluminescence NO analyzer (42). They showed that the NO levels in the stomach gas of 
neonates fed only breast milk were significantly higher than those of neonates fed formula milk with 
or without supplementary breast milk with a peak on postpartum days 2 to 5 (6.03 ± 5.73 vs. 
2.24 ± 15.71 ppm, respectively), suggesting that NO generation by breast milk plays important roles 
not only in achieving bactericidal activities but also in regulating gastric mucosal blood flow and 
mucus formation. 
 
Effects of nitrite in breast milk on the gastrointestinal tract  
Infantile Hypertrophic Pyloric Stenosis 
Another disease in early infancy relevant to feeding practice is infantile hypertrophic pyloric stenosis 
(IHPS). Although IHPS may be reportedly caused by several variables, including genetic, 
environmental, and mechanical factors (49-51), several studies have reported that NO deficiency in 
the gastric pylorus is significantly involved in the onset of IHPS (52). Nitrite in breast milk may play 
an important role in regulating gastric motility and tone of the pyloric sphincter in the stomach.  
The mouse model lacking the nNOS gene showed marked enlargement of the stomach with 
hypertrophy of the pyloric sphincter and circular muscle layer (53). Chung et al. showed the etiological 
role of the gene for nNOS in IHPS, suggesting that nNOS is a susceptibility locus for this lesion (54). 
Barbosa et al. administered L-NAME to pregnant rats and their newborns, demonstrating that newborns 
exhibited IHPS (55). As for humans, Abel reported reduced nNOS expression in the pyloric muscle 
layers and myenteric plexus obtained from the patients with IHPS using immunohistochemical staining. 
Kusafuka also reported that the transcriptional levels of nNOS were reduced in IHPS specimens 
compared with controls (56). Huang further observed that plasma nitrite levels were significantly lower 
in patients with IHPS than in controls (53).  
Although epidemiological studies have not so far revealed the evidence that NO deficiency is the 
direct cause of IHPS, an increased risk of IHPS is significantly observed in formula-fed infants 
compared with breast-fed infants (57). Krogh et al. also reported that bottle-fed infants experienced a 
4.6-fold higher risk of IHPS compared with infants who were not bottle-fed and emphasized the 
advantage of exclusive breastfeeding in the first month after birth to prevent IHPS development (58). 
These findings suggest that stomach and pyloric relaxation are dependent on NO generation, at least 
during early infancy, and its absence is significantly associated with pyloric muscle hypertrophy (50), 
which frequently occurs in a couple of weeks after birth. It can be established in  future studies 





Necrotizing Enterocolitis and Transfusion-Related Acute Gut Injury 
Necrotizing enterocolitis (NEC) is characterized by decreased gastrointestinal blood flow and 
pathogenic bacterial invasion following the breakdown of the mucus barrier lining the lumen of the 
gut. In particular, neonates born at extremely low gestational ages have a strong tendency to be exposed 
to ischemia of the gastrointestinal tract during periods of increased oxygen demand (e.g., enteral 
feeding), which is likely to cause ischemia-related acute gut injury in premature infants (59). Although 
prematurity is the leading risk factor for NEC development, breastfeeding has been demonstrated as 
the most important protective strategy against NEC (60). While there are several components in breast 
milk that are thought to be protective in preventing NEC, including lactoferrin, various growth factors, 
and non-digestible carbohydrates, leading to normal microbial colonization of the gut (61, 62), Yazji 
et al. showed that NO bioactivity is endogenously decreased due to toll-like receptor 4-mediated 
reduction of eNOS expression in the mouse model suffering from NEC. They also demonstrated that 
the addition of nitrate and nitrite to the formula milk significantly restored intestinal microcirculation, 
decreased the amount of pro-inflammatory cytokine expression in the intestine, and reduced the NEC 
severity of this model through the dietary nitrate–nitrite–NO pathway (63). This study provides a 
practical insight into the protective mechanism of breast milk against this disease and suggests that 
NO transfer via dietary nitrite is clinically involved in NO bioavailability, including vasodilatory 
effects in the gastrointestinal system.  
Recent studies have further reported that the transfusion of premature infants with anemia causes 
transfusion-related acute gut injuries, including NEC (64). Because the intestinal microvascular blood 
flow in premature infants with anemia is dependent on NO-based hypoxic vasodilation, decreased NO 
utilization in the intestinal blood perfusion by erythrocytes may be responsible for the onset of NEC. 
A recent growing body of evidence suggests that the effects of processing and storage on erythrocytes 
not only significantly decrease the SNO-Hb content and erythrocyte-dependent vasodilatory activity 
(65), but also, on the contrary, increased hemolysis and NO scavenging by cell-free Hb, which 
scavenges NO about 400 times faster than erythrocyte-encapsulated Hb due to the absence of a 
diffusion barrier between plasma and the interior of the erythrocyte (66), consequently leading to 
vasoconstriction of blood transfusion, whereas these defects were reversed by repletion of SNO-Hb 
(65). In addition to the role of erythrocytes in NO transfer, erythrocytes have eNOS activity, which 
endogenously generates NO bioactivity from L-arginine (67), whereas L-arginine in erythrocytes is 
eliminated by arginase, whose activity is enhanced according to the storage period of blood (68, 69). 
This evidence suggests that Hb-mediated NO transfer plays an important role in preventing 
microcirculatory failure of the gastrointestinal tract and explains why breast milk rich in nitrite can be 
effective in these pathological conditions. However, Patel et al. suggested that among very low birth 
weight (VLBW) infants, severe anemia, but not erythrocyte transfusion, was associated with an 
increased risk of NEC (70). Although they did not assess NO metabolites in erythrocytes (e.g., SNO-
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Hb), unknown factors may still be involved in the onset of NEC. Further advanced studies may be 
needed to directly determine whether NO scavenging by stored RBCs is relevant to the risk of NEC. 
 
Possibility of Systemic Effects of Nitrite in Breast Milk  
Neonates are physiologically at risk of hypoxic and ischemic insults during delivery, after which they 
are exposed to a high-oxygen environment following the onset of pulmonary ventilation. Nitrite may 
confer systemic protection against this physiological oxidative stress owing to increasing evidence that 
nitrite is protective in adult models of ischemia/reperfusion injury. (71-74). Nitrite is thought to lead 
mitochondria to efficient oxygen utilization by inhibiting the activity of complex I of the electron 
transport chain via S-nitrosation, effectively decreasing mitochondrial ROS generation and subsequent 
cell damage (19). NO and other bioactive nitrogen oxide species involved in this process are produced 
in hypoxic and ischemic conditions from nitrite in the blood and tissues by the reaction with a number 
of metal-containing proteins with nitrite-reducing activity present in most of the cells, such as 
deoxygenated myoglobin and Hb, cytoglobin, neuroglobin, mitochondrial enzymes, XO, cytochrome 
P450, and eNOS (20). Therefore, increased nitrite levels in circulating blood and tissues may be 
enough to cause systemic protection from oxidative stress at birth.  
Although the effect of nitrite supplementation on systemic organs such as the lungs and heart is yet 
to be studied in the neonatal period, the treatment of persistent pulmonary hypertension of the newborn 
with inhaled NO reportedly increased the nitrite levels in the blood at least twofold, reaching 
approximately 300 nM/L (75); this concentration has been reported to have systemic effects, including 
protection of mice from hepatic infarct, increase in blood flow in the human forearm, and decrease in 
the systolic blood pressure in adults (34). Although the therapeutic effect of inhaled NO was initially 
believed to be confined to lung lesions, in the 1990s, there were reports that inhaled NO could inhibit 
platelet aggregation, followed by publications demonstrating a wide range of systemic effects of 
inhaled NO, such as the ability to decrease ischemia–reperfusion injuries of the heart and mesentery, 
thrombosis, and leukocyte adhesion and modulate systemic vascular tone (76). Ibrahim et al. reported 
that inhaled NO therapy increased the blood concentrations of nitrite, nitrate, and SNO-Hb in infants 
with pulmonary hypertension, the concentrations of which may be achievable with dietary 
supplementation of nitrite. Therefore, they speculated that these stable nitrogen oxide compounds, 
even if they are derived from diets or inhaled NO, may be carriers of NO-mediated activities circulating 
throughout the body and account for beneficial effects on the brain, heart, and other critical organs 
(75). Further studies are needed to confirm that dietary nitrite in breast milk may be directly associated 
with the protection of systemic organs from oxidative insults following physiological transfer from the 
fetus to the neonate. 
 
Nursing of premature infants in neonatal intensive care units 
Separate consideration of nitrite intake would be needed for nursing of premature infants in neonatal 
intensive care units (NICU). Newborn infants in NICU are fed with widely varying concentrations of 
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nitrate and nitrite. Nitrite intake is limited for preterm infants compared with term infants in NICU 
where initial feeds may be delayed and formula milk with lower nitrite concentrations may be given. 
Even if breast milk is given, the nitrite concentrations in the breast milk of mothers of premature infants 
are significantly lower than those of mothers of term infants (77). Furthermore, nitrite intake decreases 
by 50%–75% due to storage and freeze-thawing of breast milk prior to ingestion because nitrite is 
oxidized to nitrate by lactoperoxidase, resulting in a decrease in nitrite bioavailability by the time of 
feeding. The intake of nitrate and nitrite from parenteral nutrition may be lower than that from breast 
milk (77).  
Although NICU may be the place where an increase in NO bioavailability from nitrite has to be 
considered preferentially for premature infants, there have not been, so far, enough data and discussion 
to precisely resolve this issue. Therefore, further clinical research will be performed to determine the 
beneficial effects of nitrite in the breast milk for the nursing of preterm infants in the NICU.   
 
CONCLUSION 
At birth, although neonates experience the most dramatic environmental shift from intrauterine to 
extrauterine life, their respiratory, circulatory, and metabolic systems can adapt efficiently to the new 
environment. NO may be involved in this physiological process to help the successful adaptation to 
environmental changes. Although the effectiveness of nitrite intake in the neonatal period compared to 
that in adults with various lifestyle-related diseases remains unclear, nitrite in breast milk in early 
infancy appears to compensate for the lack of the enterosalivary-nitrate-nitrite-NO pathway. More 
detailed research should be carried out focusing on the contribution of nitrite in breast milk to NO 
bioactivity in neonatal physiology and pathophysiology. Hopefully, this review will stimulate the 
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Figure 1.  
Nitrite pool and interactions with the transport of NO activities. 
There are two major sources of nitrite in the whole blood and tissues (nitrite pool): endogenous nitrite 
following the oxidation of NOS-derived NO as well as dietary nitrite via the enterosalivary pathway. 
The nitrite in the pool is transduced to NO bioactivity by circulating and tissue-bound nitrite reductases 
in hypoxia and acidosis. Erythrocytes function as physiological transporters of NO bioactivity. 
Deoxygenated Hb possesses nitrite reductase activity and reduces nitrite to NO during artery-to-vein 
transit, followed by the formation of Fe-NO Hb in the erythrocytes and subsequent NO release to other 
thiol acceptors to form plasma and other cellular SNOs for systemic NO bioactivity.  
NO, nitric oxide; eNOS, endothelial nitric oxide synthase; Hb, hemoglobin; oxyHb, oxygenated 
hemoglobin; deoxyHb, deoxygenated hemoglobin; Fe-NO Hb, iron nitrosyl hemoglobin; SNOs, S-
nitrosothiols. 
 
Figure 2.  
Plasma nitrite concentrations in fetal sheep at birth. 
Within 15 min following birth, plasma nitrite concentrations fell after umbilical cord ligation and 
ventilation initiation by more than 60% (*P < 0.001 compared with baseline) and remained lower than 
baseline, 60, 120, and 180 min after birth. Figure adapted from reference (33). 
 
Figure 3. 
Physiological factors that reduce nitrite-mediated NO bioactivity in neonates. 
 
Figure 4. 
Intragastric generation of NO in neonates.  
In total, 149 samples of gas were collected from the stomachs of 31 healthy, full-term neonates. The 
concentrations of NO in gases collected from the lumen of the neonatal stomach were measured using 
a NO chemiluminescence analyzer. Infants were divided into 2 groups: A (n=17), fed on breast milk 
only; B (n=14), fed on formulas with/without supplementary breast milk. The incidence of abnormally 
high concentrations of NO > 7.72 ppm (M ±2SD) and the average peak levels in Group A were 
significantly higher than those in Group B. Each line represents one individual. Figure adapted from 
















































































































































































Colostrum 0.19 ± 0.03 0.08 ± 0.02 1.43 ± 0.24 0.60 ± 0.15 
Transition 0.52 ± 0.10 0.001 ± 0.001 3.90 ± 0.75 0.008 ± 0.008 
Mature 0.31 ± 0.02 0.001 ± 0.001 2.32 ± 0.21 0.008 ± 0.008 
The sample means were based on 12–50 individual samples in triplicate. The daily intake of nitrate 





Comparison of the concentrations and daily intakes of nitrite among breast and formula milk in humans 
and drinking water in a rat model 
 




 (mg/kg BW/day) 
ADI  0.06  
Hord (human) 
Colostrum 0.08 ± 0.02  0.2  
Transition–mature 0.001 ± 0.001  0.0027  
Iizuka (human) 
Colostrum 0.2 ± 0.024  0.5  
Formula 0.065 ± 0.024  0.16  
Kanematsu (rat) 
0.1  0.1  
1.0  1.0 
 
The daily intake of nitrite (mg/kg BW/day) was calculated as 3.0 kg of BW and 750 mL of intake/day 
in humans and 300 g of BW and 30 mL of water intake/day in rats. BW, body weight; ADI, acceptable 
daily intake. Table is reproduced from references (2), (40), and (41). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
